The American Journal of Medicine
Volume 122, Issue 11 , Pages 992-997 , November 2009

Assessing Fracture Risk and Effects of Osteoporosis Drugs: Bone Mineral Density and Beyond

  • K. Shawn Davison, PhD

      Affiliations

    • Department of Medicine, Division of Rheumatology and Immunology, Laval University, Quebec, PQ, Canada
    • Corresponding Author InformationReprint requests should be addressed to K. Shawn Davison, PhD, via e-mail
    • ,
  • David L. Kendler, MD

      Affiliations

    • Department of Medicine, University of British Columbia, Vancouver, BC, Canada
    • ,
  • Patrick Ammann, PhD

      Affiliations

    • Division of Bone Diseases, World Health Organization Collaborating Centre for Osteoporosis Prevention, Department of Rehabilitation and Geriatrics, University Hospitals, Geneva, Switzerland
    • ,
  • Douglas C. Bauer, MD

      Affiliations

    • Division of General Internal Medicine, University of California, San Francisco, Calif
    • ,
  • David W. Dempster, PhD

      Affiliations

    • Regional Bone Center, Helen Hayes Hospital, West Haverstraw, New York
    • ,
  • Larry Dian, MD

      Affiliations

    • Department of Medicine, University of British Columbia, Vancouver, BC, Canada
    • ,
  • David A. Hanley, MD

      Affiliations

    • Department of Medicine, Faculty of Medicine, University of Calgary, Calgary, AB, Canada
    • ,
  • Steven T. Harris, MD

      Affiliations

    • University of California, San Francisco, Calif
    • ,
  • Michael R. McClung, MD

      Affiliations

    • Oregon Osteoporosis Center, Portland
    • ,
  • Wojciech P. Olszynski, MD, PhD

      Affiliations

    • Department of Medicine, University of Saskatchewan, Saskatoon, SK, Canada
    • ,
  • Chui K. Yuen, MD

      Affiliations

    • Department of Obstetrics, Gynecology, and Reproductive Sciences, University of Manitoba, and Manitoba Clinic, Winnipeg, MB, Canada

References 

  1. Johnell O, Kanis JA, Oden A, et al. Predictive value of BMD for hip and other fractures. J Bone Miner Res. 2005;20:1185–1194
  2. Cranney A, Jamal SA, Tsang JF, Josse RG, Leslie WD. Low bone mineral density and fracture burden in postmenopausal women. CMAJ. 2007;177:575–580
  3. Kanis JA, Oden A, Johnell O, et al. The use of clinical risk factors enhances the performance of BMD in the prediction of hip and osteoporotic fractures in men and women. Osteoporos Int. 2007;18:1033–1046
  4. Brown JP, Josse RG. 2002 clinical practice guidelines for the diagnosis and management of osteoporosis in Canada. CMAJ. 2002;167:S1–S34
  5. Kanis JA, Johnell O, De Laet C, et al. A meta-analysis of previous fracture and subsequent fracture risk. Bone. 2004;35:375–382
  6. Gallacher SJ, Gallagher AP, McQuillian C, Mitchell PJ, Dixon T. The prevalence of vertebral fracture amongst patients presenting with non-vertebral fractures. Osteoporos Int. 2007;18:185–192
  7. Lentle BC, Brown JP, Khan A, et al. Recognizing and reporting vertebral fractures: reducing the risk of future osteoporotic fractures. Can Assoc Radiol J. 2007;58:27–36
  8. Siminoski K, Jiang G, Adachi JD, et al. Accuracy of height loss during prospective monitoring for detection of incident vertebral fractures. Osteoporos Int. 2005;16:403–410
  9. Leslie WD, Lix LM, Tsang JF, Caetano PA. Single-site vs multisite bone density measurement for fracture prediction. Arch Intern Med. 2007;167:1641–1647
  10. Yu W, Gluer CC, Fuerst T, et al. Influence of degenerative joint disease on spinal bone mineral measurements in postmenopausal women. Calcif Tissue Int. 1995;57:169–174
  11. Baim S, Wilson CR, Lewiecki EM, Luckey MM, Downs RW, Lentle BC. Precision assessment and radiation safety for dual-energy x-ray absorptiometry: position paper of the International Society for Clinical Densitometry. J Clin Densitom. 2005;8:371–378
  12. Sarkar S, Mitlak BH, Wong M, Stock JL, Black DM, Harper KD. Relationships between bone mineral density and incident vertebral fracture risk with raloxifene therapy. J Bone Miner Res. 2002;17:1–10
  13. Chapurlat RD, Palermo L, Ramsay P, Cummings SR. Risk of fracture among women who lose bone density during treatment with alendronate (The Fracture Intervention Trial). Osteoporos Int. 2005;16:842–848
  14. Frisoli A, Paula AP, Pinheiro M, et al. Hip axis length as an independent risk factor for hip fracture independently of femoral bone mineral density in Caucasian elderly Brazilian women. Bone. 2005;37:871–875
  15. Rivadeneira F, Zillikens MC, De Laet CE, et al. Femoral neck BMD is a strong predictor of hip fracture susceptibility in elderly men and women because it detects cortical bone instability: the Rotterdam Study. J Bone Miner Res. 2007;22:1781–1790
  16. Krieg MA, Barkmann R, Gonnelli S, et al. Quantitative ultrasound in the management of osteoporosis: the 2007 ISCD Official Positions. J Clin Densitom. 2008;11:163–187
  17. Keaveny TM, Donley DW, Hoffmann PF, Mitlak BH, Glass EV, San Martin JA. Effects of teriparatide and alendronate on vertebral strength as assessed by finite element modeling of QCT scans in women with osteoporosis. J Bone Miner Res. 2007;22:149–157
  18. MacNeil JA, Boyd SK. Improved reproducibility of high-resolution peripheral quantitative computed tomography for measurement of bone quality. Med Eng Phys. 2008;30:792–799
  19. Wehrli FW, Song HK, Saha PK, Wright AC. Quantitative MRI for the assessment of bone structure and function. NMR Biomed. 2006;19:731–764
  20. Seeman E. Reduced bone formation and increased bone resorption: rational targets for the treatment of osteoporosis. Osteoporos Int. 2003;14(Suppl 3):S2–S8Epub 2003 March 19
  21. Weinstein RS, Parfitt AM, Marcus R, Greenwald M, Crans G, Muchmore DB. Effects of raloxifene, hormone replacement therapy, and placebo on bone turnover in postmenopausal women. Osteoporos Int. 2003;14:814–822
  22. Garnero P. Biomarkers for osteoporosis management: utility in diagnosis, fracture risk prediction and therapy monitoring. Mol Diagn Ther. 2008;12:157–170
  23. Eastell R, Hannon RA. Biomarkers of bone health and osteoporosis risk. Proc Nutr Soc. 2008;67:157–162
  24. Bauer DC, Garnero P, Hochberg MC, et al. Pretreatment levels of bone turnover and the antifracture efficacy of alendronate: the fracture intervention trial. J Bone Miner Res. 2006;21:292–299
  25. Delmas PD, Licata AA, Reginster JY, et al. Fracture risk reduction during treatment with teriparatide is independent of pretreatment bone turnover. Bone. 2006;39:237–243
  26. Clowes JA, Peel NF, Eastell R. The impact of monitoring on adherence and persistence with antiresorptive treatment for postmenopausal osteoporosis: a randomized controlled trial. J Clin Endocrinol Metab. 2004;89:1117–1123
  27. Delmas PD, Vrijens B, Eastell R, et al. Effect of monitoring bone turnover markers on persistence with risedronate treatment of postmenopausal osteoporosis. J Clin Endocrinol Metab. 2007;92:1296–1304
  28. Davison KS, Siminoski K, Adachi JD, et al. Bone strength: the whole is greater than the sum of its parts. Semin Arthritis Rheum. 2006;36:22–31
  29. Bischoff-Ferrari HA, Willett WC, Wong JB, Giovannucci E, Dietrich T, Dawson-Hughes B. Fracture prevention with vitamin D supplementation: a meta-analysis of randomized controlled trials. JAMA. 2005;293:2257–2264
  30. Cummings SR, Karpf DB, Harris F, et al. Improvement in spine bone density and reduction in risk of vertebral fractures during treatment with antiresorptive drugs. Am J Med. 2002;112:281–289
  31. Riggs BL, Hodgson SF, O'Fallon WM, et al. Effect of fluoride treatment on the fracture rate in postmenopausal women with osteoporosis. N Engl J Med. 1990;322:802–809
  32. Boivin GY, Chavassieux PM, Santora AC, Yates J, Meunier PJ. Alendronate increases bone strength by increasing the mean degree of mineralization of bone tissue in osteoporotic women. Bone. 2000;27:687–694
  33. Eriksen EF, Melsen F, Sod E, Barton I, Chines A. Effects of long-term risedronate on bone quality and bone turnover in women with postmenopausal osteoporosis. Bone. 2002;31:620–625
  34. Bone HG, Hosking D, Devogelaer JP, et al. Ten years' experience with alendronate for osteoporosis in postmenopausal women. N Engl J Med. 2004;350:1189–1199
  35. Stepan JJ, Burr DB, Pavo I, et al. Low bone mineral density is associated with bone microdamage accumulation in postmenopausal women with osteoporosis. Bone. 2007;41:378–385
  36. Chapurlat RD, Arlot M, Burt-Pichat B, et al. Microcrack frequency and bone remodeling in postmenopausal osteoporotic women on long-term bisphosphonates: a bone biopsy study. J Bone Miner Res. 2007;22:1502–1509
  37. Odvina CV, Zerwekh JE, Rao DS, Maalouf N, Gottschalk FA, Pak CY. Severely suppressed bone turnover: a potential complication of alendronate therapy. J Clin Endocrinol Metab. 2005;90:1294–1301
  38. Khosla S, Burr D, Cauley J, et al. Bisphosphonate-associated osteonecrosis of the jaw: report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res. 2007;22:1479–1491
  39. Khan AA, Sandor GK, Dore E, et al. Canadian consensus practice guidelines for bisphosphonate associated osteonecrosis of the jaw. J Rheumatol. 2008;35:1391–1397
  40. Cranney A, Tugwell P, Zytaruk N, et al. Meta-analyses of therapies for postmenopausal osteoporosis (IV. Meta-analysis of raloxifene for the prevention and treatment of postmenopausal osteoporosis). Endocr Rev. 2002;23:524–528
  41. Miller PD, Chines AA, Christiansen C, et al. Effects of bazedoxifene on BMD and bone turnover in postmenopausal women: 2-yr results of a randomized, double-blind, placebo-, and active-controlled study. J Bone Miner Res. 2008;23:525–535
  42. Silverman SL, Christiansen C, Genant HK, et al. Efficacy of bazedoxifene in reducing new vertebral fracture risk in postmenopausal women with osteoporosis: results from a 3-year, randomized, placebo-, and active-controlled clinical trial. J Bone Miner Res. 2008;23:1923–1934
  43. McClung MR, Siris E, Cummings S, et al. Prevention of bone loss in postmenopausal women treated with lasofoxifene compared with raloxifene. Menopause. 2006;13:377–386
  44. Cummings SR, Eastell R, Ensrud K, et al. The effects of lasofoxifene on fractures and breast cancer: 3-year results from the PEARL Trial. J Bone Miner Res. 2008;23:S81
  45. Draper MW, Plouffe L. Endometrial effects of bazedoxifene acetate, a novel selective estrogen receptor modulator, in postmenopausal women. Obstet Gynecol. 2005;106:1110–1111
  46. McClung MR, Lewiecki EM, Cohen SB, et al. Denosumab in postmenopausal women with low bone mineral density. N Engl J Med. 2006;354:821–831
  47. Miller PD, Bolognese MA, Lewiecki EM, et al. Effect of denosumab on bone density and turnover in postmenopausal women with low bone mass after long-term continued, discontinued, and restarting of therapy: a randomized blinded phase 2 clinical trial. Bone. 2008;43:222–229
  48. Kendler D, Roux C, Benhamou CL, et al. Effects of denosumab on bone mineral density and bone turnover in postmenopausal women transitioning from alendronate therapy. J Bone Miner Res. 9 Jul 13 [Epub ahead of print].
  49. Cummings SR, San Martin J, McClung MR, et al. Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med. 2009;361:756–765
  50. McClung MR, San MJ, Miller PD, et al. Opposite bone remodeling effects of teriparatide and alendronate in increasing bone mass. Arch Intern Med. 2005;165:1762–1768
  51. Paschalis EP, Glass EV, Donley DW, Eriksen EF. Bone mineral and collagen quality in iliac crest biopsies of patients given teriparatide: new results from the fracture prevention trial. J Clin Endocrinol Metab. 2005;90:4644–4649
  52. Jilka RL, Weinstein RS, Bellido T, Roberson P, Parfitt AM, Manolagas SC. Increased bone formation by prevention of osteoblast apoptosis with parathyroid hormone. J Clin Invest. 1999;104:439–446
  53. Keaveny TM, Donley DW, Hoffmann PF, Mitlak BH, Glass EV, San Martin JA. Effects of teriparatide and alendronate on vertebral strength as assessed by finite element modeling of QCT scans in women with osteoporosis. J Bone Miner Res. 2007;22:149–157
  54. Neer RM, Arnaud CD, Zanchetta JR, et al. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med. 2001;344:1434–1441
  55. Black DM, Bilezikian JP, Ensrud KE, et al. One year of alendronate after one year of parathyroid hormone (1-84) for osteoporosis. N Engl J Med. 2005;353:555–565
  56. Reginster JY, Felsenberg D, Boonen S, et al. Effects of long-term strontium ranelate treatment on the risk of nonvertebral and vertebral fractures in postmenopausal osteoporosis: Results of a five-year, randomized, placebo-controlled trial. Arthritis Rheum. 2008;58:1687–1695
  57. Arlot ME, Jiang Y, Genant HK, et al. Histomorphometric and microCT analysis of bone biopsies from postmenopausal osteoporotic women treated with strontium ranelate. J Bone Miner Res. 2008;23:215–222

 Funding: Unrestricted educational support from Amgen Canada, Servier Canada, The Alliance for Better Bone Health (sanofi-aventis and P&G Pharmaceuticals), Eli Lilly Canada, Novartis Canada, and Wyeth Canada.

 Conflict of Interest: Dr Davison has received honoraria from and has acted as a consultant for Merck, Amgen, Servier, Procter & Gamble and sanofi-aventis. Dr Kendler consults for, receives research grants from, or is on speakers bureau for Procter & Gamble, Merck, Novartis, Eli Lilly, Wyeth, GlaxoSmithKline, Biosante, Servier, Amgen, Johnson & Johnson, and Pfizer. Dr Bauer has received research funding from Amgen and Novartis. Dr Dian receives research grants from, or is on speakers bureau for Amgen, Novartis, Pfizer, Lundbeck, Merck, Procter & Gamble and sanofi-aventis. Dr Hanley has been a consultant or on a speaker's bureau for Amgen, Eli Lilly, Merck Frosst Canada, Novartis, Pfizer, Procter & Gamble Pharmaceuticals, sanofi-aventis and Servier, and he has conducted clinical trials for Procter & Gamble Pharmaceuticals. Dr Harris has given presentations sponsored by and has acted as a consultant to Amgen, GlaxoSmithKline, Eli Lilly, Merck, Novartis, Procter & Gamble, Roche, sanofi-aventis, and Wyeth. Dr McClung, receiving consulting fees or participating on paid advisory boards for Amgen, Eli Lilly, Merck, and Novartis and receiving lecture fees from Eli Lilly, Novartis, Merck, and sanofi-aventis and grant support from Amgen, GlaxoSmithKline, Eli Lilly, Merck, Novartis, Procter & Gamble, Roche, AstraZeneca, Nordic Bioscience, Radius, and sanofi-aventis. Dr Olszynski has been a consultant or on a speaker's bureau for Amgen, Eli Lilly, Merck Frosst Canada, Novartis, Pfizer, Procter & Gamble Pharmaceuticals and sanofi-aventis, and he has conducted clinical trials for Procter & Gamble Pharmaceuticals. Dr Yuen has received research grants from and is a consultant for Wyeth.

 Authorship: All authors had access to the data and played a role in writing this manuscript.

PII: S0002-9343(09)00660-3

doi: 10.1016/j.amjmed.2009.05.018

The American Journal of Medicine
Volume 122, Issue 11 , Pages 992-997 , November 2009

Article Tools